Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Critical Care
Published in: Critical Care 1/2019

Open Access 01-12-2019 | Letter

Optimizing ceftolozane-tazobactam dosage in critically ill patients during continuous venovenous hemodiafiltration

Authors: Gerardo Aguilar, Rafael Ferriols, Sara Martínez-Castro, Carlos Ezquer, Ernesto Pastor, José A. Carbonell, Manuel Alós, David Navarro

Published in: Critical Care | Issue 1/2019

Login to get access

Excerpt

Ceftolozane-tazobactam (C/T), the combination of a new cephalosporin with a classic β-lactamase inhibitor, is currently considered the most active betalactam antibiotic against P. aeruginosa [1]. Despite several case reports on C/T pharmacokinetics in critically ill patients during continuous renal replacement therapy (CRRT) [2‐4], the optimal dose in this clinical scenario still remains unclear [5]. …
Literature
1.
Montravers P, Bassetti M. The ideal patient profile for new beta-lactam/beta-lactamase inhibitors. Curr Opin Infect Dis. 2018;31(6):587–e93.CrossRef
2.
Oliver WD, Heil EL, Gonzales JP, Mehrotra S, Robinett K, Saleeb P, Nicolau DP. Ceftolozane-tazobactam pharmacokinetics in a critically ill patient on continuous venovenous hemofiltration. Antimicrob Agents Chemother. 2015;60(3):1899–901.CrossRef
3.
Kuti JL, Ghazi IM, Quintiliani R Jr, Shore E, Nicolau DP. Treatment of multidrug-resistant Pseudomonas aeruginosa with ceftolozane/tazobactam in a critically ill patient receiving continuous venovenous haemodiafiltration. Int J Antimicrob Agents. 2016;48:342–3.CrossRef
4.
Bremmer DN, Nicolau DP, Burcham P, Chunduri A, Shidham G, Bauer KA. Ceftolozane/tazobactam pharmacokinetics in a critically ill adult receiving continuous renal replacement therapy. Pharmacotherapy. 2016;36:e30–e3.CrossRef
5.
Bassetti M, Castaldo N, Cattelan A, Mussini C, Righi E, Tascini C, et al. Ceftolozane/tazobactam for the treatment of serious P. aeruginosa infections: a multicenter nationwide clinical experience. Int J Antimicrob Agents. 2018; [Epub ahead of print].
Metadata
Title
Optimizing ceftolozane-tazobactam dosage in critically ill patients during continuous venovenous hemodiafiltration
Authors
Gerardo Aguilar
Rafael Ferriols
Sara Martínez-Castro
Carlos Ezquer
Ernesto Pastor
José A. Carbonell
Manuel Alós
David Navarro
Publication date
01-12-2019
Publisher
BioMed Central
Published in
Critical Care / Issue 1/2019
Electronic ISSN: 1364-8535
DOI
https://doi.org/10.1186/s13054-019-2434-5

Other articles of this Issue 1/2019

Critical Care 1/2019 Go to the issue

Letter

Response to “Weaning order of vasoactive drugs”

Letter

Prognostic performance of age-adapted SOFA and qSOFA in septic children

Research

Examining the weekend effect across ICU performance metrics

Review

Mechanical Circulatory Support Devices for Cardiogenic Shock: State of the Art

Editorial

Obituary Brian P. Kavanagh, MD

Review

The aftermath of acute kidney injury: a narrative review of long-term mortality and renal function